Source: https://www.federalregister.gov/documents/2012/08/09/2012-19498/new-animal-drugs-cephalexin-fentanyl-milbemycin-oxime-and-praziquantel
Timestamp: 2017-11-22 04:25:18
Document Index: 441991081

Matched Legal Cases: ['arts 510', '§\u2009510', '§\u2009520', '§\u2009510', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009520', '§\u2009524', '§\u2009510']

Federal Register :: New Animal Drugs; Cephalexin; Fentanyl; Milbemycin Oxime and Praziquantel
New Animal Drugs; Cephalexin; Fentanyl; Milbemycin Oxime and Praziquantel
A Rule by the Food and Drug Administration on 08/09/2012
This rule is effective August 9, 2012.
https://www.federalregister.gov/d/2012-19498 https://www.federalregister.gov/d/2012-19498
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during June 2012. FDA is also informing the public of the availability of summaries the basis of approval and of environmental review documents, where applicable.
FDA's Center for Veterinary Medicine is adopting use of a monthly Federal Register document to codify approval actions for new animal drug applications (NADAs) and abbreviated new animal drug application (ANADAs). CVM will no longer publish a separate rule for each action. This approach will allow a more efficient use of available resources.
In this document, FDA is amending the animal drug regulations to reflect the original and supplemental approval actions during June 2012, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm.
Table 1—Original and Supplemental NADAs and ANADAs Approved During June 2012
141-326 Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137 RILEXINE (cephalexin) Chewable Tablets for Dogs Original approval for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius New 520.376 yes CE 1
141-337 Nexcyon Pharmaceuticals, Inc., 644 W. Washington Ave., Madison, WI 53703 RECUVYRA (fentanyl) Transdermal Solution Original approval for control of postoperative pain associated with surgical procedures in dogs New 524.916 yes CE 1
141-338 Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408 INTERCEPTOR SPECTRUM (milbemycin oxime/praziquantel) Chewable Tablets Original approval for prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis, and E. granulosus) infections in dogs and puppies two pounds of body weight or greater and six weeks of age and older New 520.1445 yes CE 1
1 The agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment (EA) or an environmental impact statement (EIS) because it is of a type that does not individually or cumulatively have a significant effect on the human environment.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, and 524 are amended as follows:
2. In § 510.600, in the table in paragraph (c)(1), alphabetically add an entry for “Nexcyon Pharmaceuticals, Inc.”; and in the table in paragraph (c)(2), numerically add an entry for “050929” to read as follows:
Nexcyon Pharmaceuticals, Inc., 644 W. Washington Ave., Madison, WI 53703 050929
050929 Nexcyon Pharmaceuticals, Inc., 644 W. Washington Ave., Madison, WI 53703
4. Section 520.376 is added to read as follows:
§ 520.376
(a) Specifications. Each chewable tablet contains 75, 150, 300, or 600 milligrams (mg) cephalexin.
(b) Sponsor. See No. 051311 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Dogs—(i) Amount. Administer 22 mg per kilogram of body weight twice daily for 28 days.
(ii) Indications for use. For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.
§ 520.1445
[Redesignated as § 520.1441]
§ 520.1446
[Redesignated as § 520.1443]
5. Redesignate §§ 520.1445 and 520.1446 as §§ 520.1441 and 520.1443, respectively.
6. Revise the section heading of newly redesignated § 520.1445 to read as follows:
§ 520.1441
7. Revise the section heading of newly redesignated § 520.1446 to read as follows:
§ 520.1443
Milbemycin oxime and lufenuron.
8. Add new § 520.1445 to read as follows:
Milbemycin oxime and praziquantel.
(1) 2.3 milligrams (mg) milbemycin oxime and 22.8 mg praziquantel;
(2) 5.75 mg milbemycin oxime and 57 mg praziquantel;
(3) 11.5 mg milbemycin oxime and 114 mg praziquantel; or
(4) 23 mg milbemycin oxime and 228 mg praziquantel.
(c) Conditions of use—(1) Dogs—(i) Amount. Administer orally, once a month, a minimum dosage of 0.23 mg per pound (mg/lb) of body weight (0.5 mg per kilogram (mg/kg)) milbemycin oxime and 2.28 mg/lb of body weight (5 mg/kg) praziquantel.
(ii) Indications for use. For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis, and E. granulosus) infections in dogs and puppies 2 pounds of body weight or greater and 6 weeks of age and older.
10. Add § 524.916 to read as follows:
(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) fentanyl.
(b) Sponsor. See No. 050929 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Dogs—(i) Amount. 1.2 mg/lb (2.7 mg/kg) applied topically to the dorsal scapular area 2 to 4 hours prior to surgery.
(ii) Indications for use. For the control of postoperative pain associated with surgical procedures in dogs.
(iii) Limitations. Fentanyl is a Class II controlled substance. Observe all “black-box warnings” on product labeling. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[FR Doc. 2012-19498 Filed 8-8-12; 8:45 am]